Search Results

Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior

LEXINGTON, Mass. , Feb. 13, 2020 /PRNewswire/ -- Promedior, Inc. today announced the successful completion of its previously announced sale to Roche (SIX: RO, ROG; OTCQX: RHHBY). With this acquisition, Roche obtained full rights to Promedior’s entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an up

Promedior, Inc. announced that PRM-151, a novel investigational anti-fibrotic immunomodulator, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for Idiopathic Pulmonary Fibrosis.

Promedior, Inc today announced that positive safety and efficacy data from the Company’s open-label extension study of PRM-151 in patients with Idiopathic Pulmonary Fibrosis (IPF) were simultaneously published in The Lancet Respiratory Medicine and presented at the American Thoracic Society 2019 International Conference

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, announced positive safety and efficacy data from a Phase 2 study of PRM-151 in myelofibrosis (MF) patients that either failed (76%) or were ineligible for Ruxolitinib.

Promedior, Inc., announced that it has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the study of PRM-151, a novel investigational anti-fibrotic immunomodulator, in patients with Idiopathic Pulmonary Fibrosis (IPF)

Under the terms of the agreement, Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion based on the achievement of certain predetermined development, regulatory and commercial milestones.

Follows very successful 2020, with five major exits/listings: Promedior, KaNDy, Inflazome, Enterprise Therapeutics and Dyne Therapeutics